| Name | Title | Contact Details |
|---|
Araceli Biosciences is a company that develops scientific instrumentation to improve outcomes in tissue and cell based biomarker discovery, drug discovery and drug development.
BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. Today we have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. Our Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. Our mission is to provide imaginative new ways to treat disease; making a real difference for patients, and a valuable contribution to healthcare. As medicine moves from major surgery to minor procedure, no company endeavours to do more to help doctors in their quest to see more, reach further and treat smarter. We understand their needs and equip them with tools and techniques that would have seemed like science fiction only a generation ago. We invest in clinical evidence that helps demonstrate the value of our treatments to patients, doctors, and healthcare systems. With relentless curiosity we`ll work with clinicians to find elegant new ways to extend our power over disease and transform patient care. There are no limits to where our ideas will take us.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Accelerated Rehabilitation Centers is an independent, private rehabilitation practice. Physical Therapist owned with over 160 physical rehabilitation centers throughout the Midwest and Arizona.
Cellenkos is an early stage clinical biotechnology company that focuses on cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory conditions. Cellenkos is founded on the technologies arising from the laboratory investigations of Simrit Parmar, M.D. Cellenkos` lead product CK0801 delivers clinically meaningful doses of allogeneic cord blood T-regulatory cells to overcome immune dysfunction.